About Miragen Therapeutics (NASDAQ:MGEN)
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company's diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual's long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company's MyPRS test provides a whole-genomic expression profile of a patient's multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Industry, Sector and Symbol
Industry Medical Laboratories & Research
Trailing P/E Ratio37.1333333333333
Forward P/E Ratio-4.13
Sales & Book Value
Annual Sales$3.34 million
Price / Sales48.18
Price / CashN/A
Book Value($0.43) per share
Price / Book-12.95
Return on Equity-80.31%
Return on Assets-64.59%
Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions
What is Miragen Therapeutics' stock symbol?
Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."
How were Miragen Therapeutics' earnings last quarter?
Miragen Therapeutics, Inc. (NASDAQ:MGEN) released its earnings results on Wednesday, November, 8th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.12. The medical research company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $0.72 million. Miragen Therapeutics had a negative return on equity of 80.31% and a negative net margin of 720.38%. View Miragen Therapeutics' Earnings History.
Where is Miragen Therapeutics' stock going? Where will Miragen Therapeutics' stock price be in 2018?
6 brokerages have issued twelve-month target prices for Miragen Therapeutics' shares. Their predictions range from $13.00 to $29.00. On average, they anticipate Miragen Therapeutics' stock price to reach $17.90 in the next twelve months. View Analyst Ratings for Miragen Therapeutics.
What are Wall Street analysts saying about Miragen Therapeutics stock?
Here are some recent quotes from research analysts about Miragen Therapeutics stock:
- 1. Cann analysts commented, "MiRagen Therapeutics announced today positive new interim data from its phase I clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) will be presented on February 2, 2018, at the 10th Annual T-cell Lymphoma Forum in La Jolla, California. These positive results support MiRagen’s plans to initiate a phase II study of MRG-106 in CTCL in the second half of 2018. The data released today, along with the planned phase II trial design support our expectation that MRG-106 will be able to proceed to a registration phase II study, avoiding phase III trials." (2/2/2018)
- 2. According to Zacks Investment Research, "Miragen Therapeutics, Inc. is a biopharmaceutical company. It develops microRNA biology, oligonucleotide chemistry, drugs and therapies for cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Miragen Therapeutics, Inc., formerly known as Signal Genetics, is headquartered in Boulder, Colorado. " (1/25/2018)
- 3. Chardan Capital analysts commented, "We see 6 positives in the MRG-106 oral presentation at EORTC The MRG-106 oral presentation at EORTC shows promising signals on the mycosis fungoides form of CTCL. On Saturday, October 13th, at the European Organisation for Research and Treatment of Cancer (EORTC) Global Task Force meeting, miRagen Therapeutics presented new interim phase I data of microRNA-155 inhibitor, MRG-106, in the mycosis fungoides (MF) form of cutaneous t-cell lymphoma (CTCL). The results showed 22/23 (96%) of MRG-106-treated patients had improvements in skin disease, when treated with either subcutaneous (subQ) or intravenous MRG-106, as measured by the maximal change in the modified Severity Weighted Assessment Tool (mSWAT) score, which measures the severity of skin disease over a patient’s body." (10/16/2017)
Who are some of Miragen Therapeutics' key competitors?
Some companies that are related to Miragen Therapeutics include Osiris Therapeutics (OSIR), Oxford Immunotec Global (OXFD), Pulse Biosciences (PLSE), Kadmon (KDMN), BioSpecifics Technologies (BSTC), Ardelyx (ARDX), Allergy Therapeuti (AGYTF), Neos Therapeutics (NEOS), Helius Medical Technologies (HSDT), Synlogic (SYBX), Kindred Biosciences (KIN), VBI Vaccines (VBIV), Sunesis Pharmaceuticals (SNSS), Newron Pharma (NWPHF), Aceto (ACET), Tocagen (TOCA), MDXHealth (MXDHF) and AAC (AAC).
Who owns Miragen Therapeutics stock?
Miragen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.58%), Renaissance Technologies LLC (0.37%), Deutsche Bank AG (0.27%), Virtu Financial LLC (0.23%), Bank of New York Mellon Corp (0.21%) and Aveo Capital Partners LLC (0.12%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth, Kyle Lefkoff and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.
Who bought Miragen Therapeutics stock? Who is buying Miragen Therapeutics stock?
Miragen Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Deutsche Bank AG, Virtu Financial LLC, Aveo Capital Partners LLC, BlackRock Inc., Bank of New York Mellon Corp and Wells Fargo & Company MN. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy and Bruce Booth. View Insider Buying and Selling for Miragen Therapeutics.
How do I buy Miragen Therapeutics stock?
Shares of Miragen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Miragen Therapeutics' stock price today?
One share of Miragen Therapeutics stock can currently be purchased for approximately $5.57.
How big of a company is Miragen Therapeutics?
Miragen Therapeutics has a market capitalization of $158.30 million and generates $3.34 million in revenue each year. The medical research company earns $-12,670,000.00 in net income (profit) each year or $0.15 on an earnings per share basis. Miragen Therapeutics employs 45 workers across the globe.
How can I contact Miragen Therapeutics?
Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]
MarketBeat Community Rating for Miragen Therapeutics (MGEN)MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Miragen Therapeutics (NASDAQ:MGEN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$17.90||$17.90||$23.00||$23.00|
|Price Target Upside: ||102.26% upside||122.64% upside||144.16% upside||143.39% upside|
Miragen Therapeutics (NASDAQ:MGEN) Consensus Price Target History
Miragen Therapeutics (NASDAQ:MGEN) Analyst Ratings History
(Data available from 2/25/2016 forward)
Miragen Therapeutics (NASDAQ:MGEN) Earnings History and Estimates Chart
Miragen Therapeutics (NASDAQ MGEN) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.39)||($0.27)||$0.72 million||$1.63 million||View||N/A|
|8/11/2017||Q2 2017||($0.47)||($0.34)||$0.46 million||$0.72 million||View||N/A|
|5/10/2017||Q1 2017||($0.24)||($0.60)||$1.00 million||$0.46 million||View||N/A|
|3/24/2017||Q4 2016||($7.72)||$0.76 million||View||N/A|
|8/15/2016||Q2 2016||($4.05)||($3.45)||$1.00 million||$0.87 million||View||N/A|
|5/16/2016||Q116||($0.28)||($0.26)||$645.00 million||$808.00 million||View||N/A|
|3/16/2016||Q415||($0.36)||($0.28)||$0.60 million||$0.66 million||View||N/A|
|11/12/2015||Q3 2015||($5.85)||$0.50 million||View||N/A|
|5/14/2015||Q115||($0.36)||($0.45)||$1.90 million||$0.65 million||View||N/A|
|11/14/2014||Q3 2014||($0.05)||($0.43)||$1.30 million||View||N/A|
Miragen Therapeutics (NASDAQ:MGEN) Earnings Estimates
2018 EPS Consensus Estimate: ($1.44)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Miragen Therapeutics (NASDAQ:MGEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Miragen Therapeutics (NASDAQ MGEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.40%
Institutional Ownership Percentage: 23.39%
Miragen Therapeutics (NASDAQ MGEN) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/13/2018||Adam Scott Levy||Insider||Buy||9,090||$5.50||$49,995.00||10,540|| |
|2/13/2018||Bruce Booth||Director||Buy||545,454||$5.50||$2,999,997.00|| |
|12/20/2017||Thomas E. Hughes||Director||Sell||12,000||$8.00||$96,000.00|| |
|6/22/2017||Adam Scott Levy||Insider||Buy||200||$7.55||$1,510.00||200|| |
|3/10/2017||Kyle Lefkoff||Director||Sell||5,800||$14.34||$83,172.00|| |
|3/8/2017||Kyle Lefkoff||Director||Sell||15,000||$15.40||$231,000.00|| |
|2/28/2017||Kyle Lefkoff||Director||Sell||10,258||$13.89||$142,483.62|| |
|2/23/2017||Kyle Lefkoff||Director||Sell||5,902||$14.14||$83,454.28|| |
|11/20/2015||Samuel D. Riccitelli||CEO||Buy||14,000||$0.79||$11,060.00||345,130|| |
Miragen Therapeutics (NASDAQ MGEN) News Headlines
|Miragen Therapeutics, Inc. (MGEN) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - February 24 at 9:54 AM
|$1.22 Million in Sales Expected for Miragen Therapeutics, Inc. (MGEN) This Quarter|
www.americanbankingnews.com - February 15 at 6:42 AM
|Miragen Therapeutics, Inc. (MGEN) Insider Adam Scott Levy Buys 9,090 Shares|
www.americanbankingnews.com - February 13 at 6:46 PM
|Bruce Booth Purchases 545,454 Shares of Miragen Therapeutics, Inc. (MGEN) Stock|
www.americanbankingnews.com - February 13 at 6:10 PM
| Analysts Expect Miragen Therapeutics, Inc. (MGEN) Will Post Earnings of -$0.32 Per Share|
www.americanbankingnews.com - February 13 at 3:14 AM
|miRagen Therapeutics, Inc. Prices Public Offering of Common Stock|
finance.yahoo.com - February 9 at 5:01 AM
|miRagen Therapeutics (MGEN) Announces Proposed 7M Share Common Offering|
www.streetinsider.com - February 5 at 3:08 PM
|miRagen Therapeutics Announces Proposed Public Offering of Common Stock|
finance.yahoo.com - February 5 at 3:08 PM
|Miragen Therapeutics (MGEN) Rating Reiterated by Cann|
www.americanbankingnews.com - February 2 at 4:46 PM
|Miragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - January 30 at 9:39 AM
| Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Quarterly Sales of $1.22 Million|
www.americanbankingnews.com - January 29 at 8:22 AM
| Brokerages Anticipate Miragen Therapeutics, Inc. (MGEN) Will Announce Earnings of -$0.32 Per Share|
www.americanbankingnews.com - January 27 at 5:18 AM
|Zacks Investment Research Lowers Miragen Therapeutics (MGEN) to Hold|
www.americanbankingnews.com - January 25 at 6:50 AM
|miRagen Therapeutics to Present New MRG-106 Phase 1 Clinical Trial Data at the T-Cell Lymphoma Forum|
finance.yahoo.com - January 24 at 7:07 AM
|Chardan Capital Reiterates "Buy" Rating for Miragen Therapeutics (MGEN)|
www.americanbankingnews.com - January 20 at 6:28 AM
|Miragen Therapeutics (MGEN) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - January 18 at 8:28 AM
|Miragen Therapeutics (MGEN) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - January 17 at 6:10 AM
|Miragen Therapeutics (MGEN) Coverage Initiated by Analysts at Cann|
www.americanbankingnews.com - January 14 at 6:40 AM
|Oppenheimer Initiates Coverage on Miragen Therapeutics (MGEN)|
www.americanbankingnews.com - January 13 at 9:36 PM
|Miragen Could Surpass $1 Billion In Revenue In 2025, Says Biotech Analyst|
feeds.benzinga.com - January 12 at 2:03 PM
|Miragen Therapeutics (MGEN) Upgraded to Buy at Zacks Investment Research|
www.americanbankingnews.com - January 9 at 6:08 AM
|Miragen Therapeutics (MGEN) Coverage Initiated by Analysts at B. Riley|
www.americanbankingnews.com - January 6 at 11:50 PM
|Zacks Investment Research Downgrades Miragen Therapeutics (MGEN) to Hold|
www.americanbankingnews.com - January 6 at 10:04 AM
|Where Miragen Therapeutics Inc (NASDAQ:MGEN) Stands In Terms Of Earnings Growth Against Its Industry|
finance.yahoo.com - January 5 at 4:32 PM
|Miragen Therapeutics, Inc. (MGEN) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - January 5 at 10:18 AM
|miRagen Therapeutics (MGEN) Appoints Arlene Morris to Board|
www.streetinsider.com - January 5 at 10:14 AM
|miRagen Therapeutics Expands Board of Directors with Appointment of Arlene Morris|
finance.yahoo.com - January 5 at 10:14 AM
|Miragen Therapeutics Inc (NASDAQ:MGEN): Will The Growth Last?|
finance.yahoo.com - December 29 at 9:20 AM
|Can Signal Genetics (MGEN) Run Higher on Strong Earnings Estimate Revisions?|
finance.yahoo.com - December 28 at 4:35 PM
|Miragen Therapeutics, Inc. (MGEN) Director Thomas E. Hughes Sells 12,000 Shares|
www.americanbankingnews.com - December 22 at 8:39 PM
|Miragen Therapeutics Inc|
www.bloomberg.com - December 21 at 4:50 PM
|ETFs with exposure to Miragen Therapeutics, Inc. : December 21, 2017|
finance.yahoo.com - December 21 at 4:50 PM
|miRagen Therapeutics Presents New Interim Clinical Data Expanding on Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at 2017 American Society of Hematology Annual Meeting|
finance.yahoo.com - December 11 at 4:58 PM
|Head to Head Survey: Cannabis Science (CBIS) and Miragen Therapeutics (MGEN)|
www.americanbankingnews.com - December 8 at 7:42 PM
|Financial Review: Miragen Therapeutics (MGEN) vs. BG Medicine (BGMD)|
www.americanbankingnews.com - December 8 at 5:14 PM
|BG Medicine (BGMD) vs. Miragen Therapeutics (MGEN) Head-To-Head Analysis|
www.americanbankingnews.com - December 6 at 3:12 AM
|Top Insiders Are Buying These 3 'Strong Buy' Healthcare Stocks|
www.nasdaq.com - December 4 at 4:47 PM
|Financial Analysis: Signal Genetics (MGEN) vs. BG Medicine (BGMD)|
www.americanbankingnews.com - December 3 at 4:38 PM
|Reviewing Cannabis Science (CBIS) and Signal Genetics (MGEN)|
www.americanbankingnews.com - December 2 at 1:30 AM
|Signal Genetics (MGEN) Earns Buy Rating from Wedbush|
www.americanbankingnews.com - December 1 at 4:12 PM
|Head to Head Comparison: Signal Genetics (MGEN) versus BG Medicine (BGMD)|
www.americanbankingnews.com - December 1 at 3:54 PM
|Head-To-Head Contrast: Cannabis Science (CBIS) and Signal Genetics (MGEN)|
www.americanbankingnews.com - November 30 at 1:28 AM
|Head to Head Analysis: Cannabis Science (CBIS) versus Signal Genetics (MGEN)|
www.americanbankingnews.com - November 27 at 10:58 AM
|Cannabis Science (CBIS) & Signal Genetics (MGEN) Head-To-Head Review|
www.americanbankingnews.com - November 22 at 3:42 PM
|Contrasting Cannabis Science (CBIS) & Signal Genetics (MGEN)|
www.americanbankingnews.com - November 21 at 5:52 PM
|BG Medicine (BGMD) and Signal Genetics (MGEN) Critical Survey|
www.americanbankingnews.com - November 21 at 1:52 PM
|BG Medicine (BGMD) and Signal Genetics (MGEN) Head to Head Review|
www.americanbankingnews.com - November 20 at 1:30 AM
|Signal Genetics, Inc. (MGEN) Stock Rating Upgraded by Zacks Investment Research|
www.americanbankingnews.com - November 18 at 6:56 PM
|Cannabis Science (CBIS) versus Signal Genetics (MGEN) Critical Review|
www.americanbankingnews.com - November 17 at 3:08 AM
|Cannabis Science (CBIS) vs. Signal Genetics (MGEN) Head to Head Survey|
www.americanbankingnews.com - November 16 at 11:14 PM
Miragen Therapeutics (NASDAQ:MGEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Miragen Therapeutics (NASDAQ:MGEN) Income Statement, Balance Sheet and Cash Flow Statement
Miragen Therapeutics (NASDAQ MGEN) Stock Chart for Sunday, February, 25, 2018